The USFDA has issued a form 483 with 10 observations after inspection of Sun Pharma's Halol facility. The unit, however, now has a low contribution to the company’s turnover. The Halol facility was classified ‘Official Action Indicated (OAI)’ in March 2020, and was awaiting re-inspection from the US regulator. Due to the pandemic related travel restrictions, the re-inspection got delayed, and now the USFDA has issued a form 483 with observations. Sun Pharma said that the US Food and Drugs Administration (USFDA) did a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Halol facility in Gujarat from April 26 to May 9, 2022. The Company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days.
The Banking Ombudsman Scheme is introduced under which of the following sections in Banking Regulation Act, 1949?
According to the Mundell-Fleming model for a small open economy with flexible exchange rates, if the Federal Reserve cannot alter domestic int...
Which of the following statements is/are CORRECT under the Keynesian Cross (Fixed Price) Model?
When R2 = 0, the estimated line (SRF) lies
Assertion (A): Use of goods and services from which one can be excluded are pure private goods.
Reason (R): Such goods and se...
In classical linear regression model if we add in 90 in X and Y observation and re-estimate the regression model then slope coefficient
Consider the following demand curve Q=100-P in a Duopoly where in A firm is the leader and the B firm is the follower. The Marginal cost given as 20. W...
If quantities of all commodities change in the same proportion then
A rational decision maker does which of the following?
A firm finds that for the product it produces, its (own) price elasticity of demand is 4. Currently, the firm is selling 1000 units per month at Rs. 5 p...
